NO20044947L - MUC-1 antigen med redusert antall VNTR gjentagene enheter - Google Patents
MUC-1 antigen med redusert antall VNTR gjentagene enheterInfo
- Publication number
- NO20044947L NO20044947L NO20044947A NO20044947A NO20044947L NO 20044947 L NO20044947 L NO 20044947L NO 20044947 A NO20044947 A NO 20044947A NO 20044947 A NO20044947 A NO 20044947A NO 20044947 L NO20044947 L NO 20044947L
- Authority
- NO
- Norway
- Prior art keywords
- muc
- nucleic acid
- repeating units
- pharmaceutical compositions
- vntr
- Prior art date
Links
- 102100034256 Mucin-1 Human genes 0.000 title abstract 3
- 108010008707 Mucin-1 Proteins 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212046.7A GB0212046D0 (en) | 2002-05-24 | 2002-05-24 | Vaccines |
| PCT/EP2003/005594 WO2003100060A2 (en) | 2002-05-24 | 2003-05-23 | Muc-1 antigen with reduced number of vntr repeat units |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20044947D0 NO20044947D0 (no) | 2004-11-12 |
| NO20044947L true NO20044947L (no) | 2005-12-16 |
Family
ID=9937394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044947A NO20044947L (no) | 2002-05-24 | 2004-11-12 | MUC-1 antigen med redusert antall VNTR gjentagene enheter |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060251665A1 (enExample) |
| EP (1) | EP1527177A2 (enExample) |
| JP (1) | JP2005526520A (enExample) |
| KR (1) | KR20050004211A (enExample) |
| CN (1) | CN100408682C (enExample) |
| AR (1) | AR039846A1 (enExample) |
| AU (1) | AU2003240729B2 (enExample) |
| BR (1) | BR0311211A (enExample) |
| CA (1) | CA2485816A1 (enExample) |
| GB (1) | GB0212046D0 (enExample) |
| IL (1) | IL165156A0 (enExample) |
| IS (1) | IS7526A (enExample) |
| MX (1) | MXPA04011527A (enExample) |
| NO (1) | NO20044947L (enExample) |
| NZ (1) | NZ536668A (enExample) |
| PL (1) | PL374569A1 (enExample) |
| RU (1) | RU2303069C2 (enExample) |
| TW (1) | TW200407426A (enExample) |
| WO (1) | WO2003100060A2 (enExample) |
| ZA (1) | ZA200409445B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| ES2476990T3 (es) | 2003-11-12 | 2014-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sistema para tratar y prevenir cáncer de mama |
| WO2005046622A2 (en) | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| EP1848804B1 (en) * | 2005-01-28 | 2011-10-05 | Ramot at Tel Aviv University, Ltd. | Anti-muc1 alpha beta antibodies |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| WO2011156751A2 (en) * | 2010-06-11 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | Immunogenic vaccine |
| CN106215179A (zh) * | 2010-06-11 | 2016-12-14 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
| JP2014518841A (ja) * | 2011-02-24 | 2014-08-07 | オンコシレオン インク． | アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン |
| CA2954892A1 (en) * | 2016-01-19 | 2017-07-19 | Pfizer Inc. | Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens |
| AU2017336269B2 (en) * | 2016-09-28 | 2022-06-16 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| EP3794042B1 (en) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028523A (zh) * | 1995-11-30 | 2007-09-05 | 德克萨斯州立大学董事会 | 诊断和治疗肿瘤的方法及组合物 |
| CA2282300C (en) * | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6228843B1 (en) * | 1999-04-23 | 2001-05-08 | University Technology Corporation | Method of using PKC inhibiting compounds to treat vascular disease |
| WO2001018035A2 (en) * | 1999-09-08 | 2001-03-15 | Transgene S.A. | Muc-1 derived peptides |
| GB9930359D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
| WO2001057068A1 (en) * | 2000-02-01 | 2001-08-09 | The Austin Research Institute | Mucin-1 derived antigens and their use in immunotherapy |
| US20020142047A1 (en) * | 2001-01-19 | 2002-10-03 | Johnson Mark E. | Microsphere delivery of mucin peptides |
| US7125663B2 (en) * | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| EP1572918B1 (en) * | 2002-04-15 | 2011-10-19 | Oncothyreon Inc. | Synthetic glyco-lipo-peptides as vaccines |
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
-
2002
- 2002-05-24 GB GBGB0212046.7A patent/GB0212046D0/en not_active Ceased
-
2003
- 2003-05-22 AR ARP030101782A patent/AR039846A1/es unknown
- 2003-05-22 TW TW092113870A patent/TW200407426A/zh unknown
- 2003-05-23 MX MXPA04011527A patent/MXPA04011527A/es not_active Application Discontinuation
- 2003-05-23 AU AU2003240729A patent/AU2003240729B2/en not_active Ceased
- 2003-05-23 WO PCT/EP2003/005594 patent/WO2003100060A2/en not_active Ceased
- 2003-05-23 NZ NZ536668A patent/NZ536668A/en unknown
- 2003-05-23 PL PL03374569A patent/PL374569A1/xx unknown
- 2003-05-23 CA CA002485816A patent/CA2485816A1/en not_active Abandoned
- 2003-05-23 KR KR10-2004-7018958A patent/KR20050004211A/ko not_active Ceased
- 2003-05-23 US US10/515,871 patent/US20060251665A1/en not_active Abandoned
- 2003-05-23 EP EP03730134A patent/EP1527177A2/en not_active Withdrawn
- 2003-05-23 JP JP2004508299A patent/JP2005526520A/ja active Pending
- 2003-05-23 RU RU2004134331/13A patent/RU2303069C2/ru active
- 2003-05-23 BR BR0311211-0A patent/BR0311211A/pt not_active IP Right Cessation
- 2003-05-23 CN CNB038171988A patent/CN100408682C/zh not_active Expired - Fee Related
-
2004
- 2004-11-10 IL IL16515604A patent/IL165156A0/xx unknown
- 2004-11-11 IS IS7526A patent/IS7526A/is unknown
- 2004-11-12 NO NO20044947A patent/NO20044947L/no not_active Application Discontinuation
- 2004-11-23 ZA ZA200409445A patent/ZA200409445B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005526520A (ja) | 2005-09-08 |
| AU2003240729B2 (en) | 2007-12-20 |
| TW200407426A (en) | 2004-05-16 |
| ZA200409445B (en) | 2006-02-22 |
| KR20050004211A (ko) | 2005-01-12 |
| CA2485816A1 (en) | 2003-12-04 |
| MXPA04011527A (es) | 2005-09-30 |
| RU2303069C2 (ru) | 2007-07-20 |
| CN1668746A (zh) | 2005-09-14 |
| WO2003100060A3 (en) | 2004-02-19 |
| BR0311211A (pt) | 2005-03-01 |
| AU2003240729A1 (en) | 2003-12-12 |
| PL374569A1 (en) | 2005-10-31 |
| IL165156A0 (en) | 2005-12-18 |
| GB0212046D0 (en) | 2002-07-03 |
| NZ536668A (en) | 2007-01-26 |
| IS7526A (is) | 2004-11-11 |
| CN100408682C (zh) | 2008-08-06 |
| NO20044947D0 (no) | 2004-11-12 |
| WO2003100060A2 (en) | 2003-12-04 |
| RU2004134331A (ru) | 2005-08-27 |
| AR039846A1 (es) | 2005-03-02 |
| EP1527177A2 (en) | 2005-05-04 |
| US20060251665A1 (en) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ebensen et al. | The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties | |
| RU2583295C2 (ru) | Нуклеиновая кислота, содержащая или кодирующая гистоновую структуру типа "стебель-петля" и поли(а)-последовательность или сигнал полиаденилирования, для повышения экспрессии кодируемого белка | |
| BR9712852A (pt) | Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado | |
| EP2773760B1 (en) | Double-stranded rna for immunostimulation | |
| US6090791A (en) | Method for inducing mucosal immunity | |
| AU2003263552A1 (en) | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules | |
| EP2141227A3 (en) | Hyperblebbing bacterial strains and use thereof for production of vaccines | |
| CN112574997A (zh) | 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用 | |
| WO2003100060A3 (en) | Muc-1 antigen with reduced number of vntr repeat units | |
| FI902569A0 (fi) | Producering av till gonorre anslutande pi-proteiner och vaccin. | |
| HUP0302481A2 (hu) | Virulencia gének, fehérjék és alkalmazásuk | |
| DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| ATE296354T1 (de) | Methode zur plasmidstabilisierung durch in vivo deletion der antibiotikaresistenz und selektion mit einem essentiellen gen | |
| CN103012577B (zh) | 一种重组猪白细胞介素4及其编码基因和表达方法 | |
| CN112725378B (zh) | 一种人工改造的akt3环状rna及其在新冠疫苗中的应用 | |
| BR9910005A (pt) | Composição de vacina, processos para imunização contra neisseria gonorrhoeae e para preparar uma composição de vacina, sequência de dna isolada e purificada, plasmìdeo, célula hospedeira, processo para produção de uma proteìna pilina recombinante quimérica de neisseria gonorrhoeae e neisseria meningitidis, proteìna pilina recombinante quimérica isolada e purificada de neisseria gonorhoeae e neisseria meningitidis, e, processo para imunização contra neisseria muningitidis | |
| WO2002098455A3 (en) | Production of recombinant human arylsulfatase a | |
| NO20051561L (no) | Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. | |
| BRPI0519330A2 (pt) | Ácido nuclÉico isolado; vetor; cÉlula hospedeira; mÉtodo para expressar uma proteÍna; polipeptÍdeo isolado; cromoproteÍna isolada; oligonucleotÍdeo; mÉtodo para identificar um Ácido nuclÉico que codifica uma apoproteÍna de um enediina de nove membros contendo cromoproteÍna; cultura biologicamente pura de actinomadura sp. 21g792 (nrrl 30778); mÉtodo para preparar uma cromoproteÍna; mÉtodo para preparar uma cromoproteÍna modificada; mÉtodo para inibir a progressço de uma doenÇa neoplÁsica em um mamÍfero; composiÇço farmacÊutica; e composto | |
| NO20081541L (no) | Ny sjo-lus vaksine | |
| CN118542935A (zh) | 一种基于突变型p53-R175H的mRNA疫苗及其应用 | |
| Wang et al. | Role of PG0192 and PG0193 in the modulation of pro‐inflammatory cytokines in macrophages in response to Porphyromonas gingivalis | |
| CN121079313A (zh) | Ccl20启动子调控的基因表达 | |
| Madison et al. | Partial digestion of a yeast lysine transfer ribonucleic acid and reconstruction of the nucleotide sequence | |
| CN105713916B (zh) | 一种铜绿假单胞菌基因及其dna疫苗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |